Experts and Doctors on humans in South San Francisco, California, United States


Locale: South San Francisco, California, United States
Topic: humans

Top Publications

  1. Schmelzer C, Burton L, Tamony C, Schwall R, Mason A, Liegeois N. Purification and characterization of recombinant human activin B. Biochim Biophys Acta. 1990;1039:135-41 pubmed
    ..Activin B has an apparent pI of 4.6 as determined by isoelectric focusing in 6 M urea and 4.7 as determined by chromatofocusing in 6 M urea. The extinction coefficient is 1.8. ..
  2. Rothe M, Xiong J, Shu H, Williamson K, Goddard A, Goeddel D. I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction. Proc Natl Acad Sci U S A. 1996;93:8241-6 pubmed
    ..Overexpression of I-TRAF inhibits TRAF2-mediated NF-kappa B activation signaled by CD40 and both TNF receptors. Thus, I-TRAF appears as a natural regulator of TRAF function that may act by maintaining TRAFs in a latent state. ..
  3. Marsters S, Sheridan J, Donahue C, Pitti R, Gray C, Goddard A, et al. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol. 1996;6:1669-76 pubmed
    ..Apo-3 resembles TNFR1 because it can stimulate NF-kappa B activity and regulate apoptosis. Apo-3 mRNA is expressed in various tissues, consistent with the possibility that this receptor may regulate multiple signaling functions. ..
  4. Marsters S, Sheridan J, Pitti R, Huang A, Skubatch M, Baldwin D, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol. 1997;7:1003-6 pubmed
    ..Upon overexpression, DcR2 did not activate apoptosis or nuclear factor-kappaB; however, it substantially reduced cellular sensitivity to Apo2L-induced apoptosis. These results suggest that DcR2 functions as an inhibitory Apo2L receptor. ..
  5. McGrath M, Mirzadegan T, Schmidt B. Crystal structure of phenylmethanesulfonyl fluoride-treated human chymase at 1.9 A. Biochemistry. 1997;36:14318-24 pubmed
    ..Moreover, the cationic nature of S1' provides a structural basis for human chymase's poor catalytic efficiency when angiotensin II is the substrate. ..
  6. Wang Y, Spellman M. Purification and characterization of a GDP-fucose:polypeptide fucosyltransferase from Chinese hamster ovary cells. J Biol Chem. 1998;273:8112-8 pubmed
    ..This indicates that the enzyme requires proper folding of the epidermal growth factor domain for its activity. ..
  7. Qu K, Lu Y, Lin N, Singh R, Xu X, Payan D, et al. Computational and experimental studies on human misshapen/NIK-related kinase MINK-1. Curr Med Chem. 2004;11:569-82 pubmed
    ..Further medicinal chemistry compound structure optimization and kinase assays are underway. ..
  8. Dornan D, Bheddah S, Newton K, Ince W, Frantz G, Dowd P, et al. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 2004;64:7226-30 pubmed
    ..Overall, these results suggest that overexpression of COP1 contributes to the accelerated degradation of p53 protein in cancers and attenuates the tumor suppressor function of p53. ..
  9. Edosada C, Quan C, Tran T, Pham V, Wiesmann C, Fairbrother W, et al. Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Lett. 2006;580:1581-6 pubmed
    ..Thus, FAP is a narrow specificity endopeptidase and this can be exploited for inhibitor design. ..

More Information

Publications521 found, 100 shown here

  1. Dynek J, Chan S, Liu J, Zha J, Fairbrother W, Vucic D. Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res. 2008;68:3124-32 pubmed publisher
    ..Collectively, these findings implicate MITF as a major transcriptional regulator of ML-IAP expression in melanomas, and suggest that ML-IAP contributes to the prosurvival activity of MITF in melanoma progression. ..
  2. Newton K, Matsumoto M, Wertz I, Kirkpatrick D, Lill J, Tan J, et al. Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell. 2008;134:668-78 pubmed publisher
    ..Polyubiquitin editing may therefore be a general mechanism for attenuating innate immune signaling. ..
  3. Yauch R, Gould S, Scales S, Tang T, Tian H, Ahn C, et al. A paracrine requirement for hedgehog signalling in cancer. Nature. 2008;455:406-10 pubmed publisher
    ..Taken together, these studies demonstrate a paracrine requirement for Hh ligand signalling in the tumorigenesis of Hh-expressing cancers and have important implications for the development of Hh pathway antagonists in cancer. ..
  4. Dynek J, Goncharov T, Dueber E, Fedorova A, Izrael Tomasevic A, Phu L, et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J. 2010;29:4198-209 pubmed publisher
    ..Lastly, NF-?B essential modifier efficiently binds K11-linked ubiquitin chains, suggesting that this ubiquitin linkage may have a signalling role in the activation of proliferative cellular pathways. ..
  5. Mukherjee A, Badal Y, Nguyen X, Miller J, Chenna A, Tahir H, et al. Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins. PLoS ONE. 2011;6:e16443 pubmed publisher
    ..This assay system is capable of quantitatively measuring therapeutically relevant responses and enables molecular profiling of receptor networks in both preclinical and tumor models. ..
  6. Rutz S, Ouyang W. Regulation of interleukin-10 and interleukin-22 expression in T helper cells. Curr Opin Immunol. 2011;23:605-12 pubmed publisher
    ..Here we discuss a number of common aspects as well as crucial differences in the molecular regulation of both cytokines that might explain their broad, but distinct expression among Th cell subsets. ..
  7. Mukadam S, Tay S, Tran D, Wang L, Delarosa E, Khojasteh S, et al. Evaluation of time-dependent cytochrome p450 inhibition in a high-throughput, automated assay: introducing a novel area under the curve shift approach. Drug Metab Lett. 2012;6:43-53 pubmed
    ..The detailed automated methodology, assay validation, data reporting and the novel TDI AUC shift approach to describe magnitude of TDI are presented. ..
  8. Lazarin G, Haque I, Nazareth S, Iori K, Patterson A, Jacobson J, et al. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. Genet Med. 2013;15:178-86 pubmed publisher
  9. Lipari M, Li W, Moran P, Kong Beltran M, Sai T, Lai J, et al. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels. J Biol Chem. 2012;287:43482-91 pubmed publisher
    ..Therapeutic anti-PCSK9 approaches that neutralize both forms should be the most effective in preserving LDL receptors and in lowering plasma LDL cholesterol. ..
  10. Wang X, Magnuson S, Pastor R, Fan E, Hu H, Tsui V, et al. Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design. Bioorg Med Chem Lett. 2013;23:3149-53 pubmed publisher
    ..Compound 17 is a novel lead with low picomolar potency on all three Pim kinase isoforms. ..
  11. Leong S, Baxter R, Camerato T, Dai J, Wood W. Structure and functional expression of the acid-labile subunit of the insulin-like growth factor-binding protein complex. Mol Endocrinol. 1992;6:870-6 pubmed
    ..The amino acid sequence of ALS is largely composed of 18-20 leucine-rich repeats of 24 amino acids. These repeats are found in a number of diverse proteins that, like ALS, participate in protein-protein interactions. ..
  12. Masuda E, Luo Y, Young C, Shen M, Rossi A, Huang B, et al. Rab37 is a novel mast cell specific GTPase localized to secretory granules. FEBS Lett. 2000;470:61-4 pubmed
    ..These data suggest that Rab37 may play an important role in mast cell degranulation making this protein a potentially important target for therapeutic intervention in the treatment of allergy. ..
  13. Pandey A, Volkots D, Seroogy J, Rose J, Yu J, Lambing J, et al. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J Med Chem. 2002;45:3772-93 pubmed
    ..Oral administration of 75 promotes mice survival and significantly delayed disease progression in a Flt-3/ITD-mediated leukemia mouse model and shows efficacy in a nude mouse model of chronic myelomonocytic leukemia. ..
  14. Katz B, Luong C, Ho J, Somoza J, Gjerstad E, Tang J, et al. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA). J Mol Biol. 2004;344:527-47 pubmed
    ..The 6-fluoro-5-amidinobenzimidzole, CA-11, is more than 1000-fold selective against natural Ala190 protease anti-targets, and more than 100-fold selective against other Ser190 anti-targets. ..
  15. Swift S, Lorens J, Achacoso P, Nolan G. Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc Immunol. 2001;Chapter 10:Unit 10.17C pubmed publisher
    ..Finally, several methods for transfecting adherent or suspension cells with retroviruses are described. ..
  16. Shang Y, Mao Y, Batson J, Scales S, Phillips G, Lackner M, et al. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Mol Cancer Ther. 2008;7:2599-608 pubmed publisher
  17. Nakamura G, Chai N, Park S, Chiang N, Lin Z, Chiu H, et al. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe. 2013;14:93-103 pubmed publisher
    ..Furthermore, these antibodies elicit robust in vivo synergism when combined with oseltamivir, thus highlighting treatment strategies that could benefit influenza-infected patients. ..
  18. Rose B, Yokota T, Chintalgattu V, Ren S, Iruela Arispe L, Khakoo A, et al. Cardiac myocyte p38? kinase regulates angiogenesis via myocyte-endothelial cell cross-talk during stress-induced remodeling in the heart. J Biol Chem. 2017;292:12787-12800 pubmed publisher
    ..We conclude that as part of a stress-induced signaling pathway, p38 MAPK activity significantly contributes to both pathological and compensatory remodeling in the heart. ..
  19. Ashkenazi A, Ramachandran J, Capon D. Acetylcholine analogue stimulates DNA synthesis in brain-derived cells via specific muscarinic receptor subtypes. Nature. 1989;340:146-50 pubmed
  20. Hötzel I. Conservation of inner domain modules in the surface envelope glycoproteins of an ancient rabbit lentivirus and extant lentiviruses and betaretroviruses. Virology. 2008;372:201-7 pubmed
  21. Sternlicht M, Sunnarborg S. The ADAM17-amphiregulin-EGFR axis in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2008;13:181-94 pubmed publisher
  22. ZHONG C, Qu X, Tan M, Meng Y, Ferrara N. Characterization and regulation of bv8 in human blood cells. Clin Cancer Res. 2009;15:2675-84 pubmed publisher
    ..These results provide the basis for further investigation of the pathophysiologic role of Bv8 in human tumors and inflammatory disorders and, potentially, for therapeutic application of Bv8 inhibitors. ..
  23. Bourhis E, Lingel A, Phung Q, Fairbrother W, Cochran A. Phosphorylation of a borealin dimerization domain is required for proper chromosome segregation. Biochemistry. 2009;48:6783-93 pubmed publisher
    ..Mutation of this single residue to alanine or valine impairs Aurora B activity during mitosis and causes chromosome segregation defects. This study reveals that Mps1 regulates the CPC through a novel Borealin domain. ..
  24. Parlati F, Lee S, Aujay M, Suzuki E, Levitsky K, Lorens J, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 2009;114:3439-47 pubmed publisher
    ..These data support a hypothesis that hematologic tumor cells are uniquely sensitive to CT-L inhibition and provide a mechanistic understanding of the clinical safety profile and antitumor activity of proteasome inhibitors. ..
  25. Kelley B, Jankowski M, Booth J. An improved manufacturing process for Xyntha/ReFacto AF. Haemophilia. 2010;16:717-25 pubmed publisher
    ..The product produced by the improved manufacturing process is named Xyntha/ReFacto AF. ..
  26. Emu B, Luca D, Offutt C, Grogan J, Rojkovich B, Williams M, et al. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial. Arthritis Res Ther. 2012;14:R6 pubmed publisher
    ..4% for placebo. Pateclizumabwas generally well-tolerated in RA patients. Preliminary evidence of clinical activity was observed in active RA patients at the dose level targeted for clinical effect. ..
  27. Poms A, Turner M, Farber H, Meltzer L, McGoon M. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest. 2013;144:169-176 pubmed publisher
    ..Further investigation of the effects of treating these comorbidities in patients with PAH is warranted.; Identifier: NCT00370214; URL: ..
  28. Baltgalvis K, White K, Li W, Claypool M, Lang W, Alcantara R, et al. Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice. Am J Physiol Heart Circ Physiol. 2014;306:H1128-45 pubmed publisher
  29. Eigenbrot C, Randal M, Quan C, Burnier J, O Connell L, Rinderknecht E, et al. X-ray structure of human relaxin at 1.5 A. Comparison to insulin and implications for receptor binding determinants. J Mol Biol. 1991;221:15-21 pubmed
    ..However, because the dimer contacts of relaxin and insulin are quite different, it appears that these two structurally related hormones have evolved somewhat dissimilar mechanisms for receptor binding. ..
  30. Joly J, Swartz J. Protein folding activities of Escherichia coli protein disulfide isomerase. Biochemistry. 1994;33:4231-6 pubmed
    ..The reduced form of the protein is a disulfide isomerase while the oxidized protein can assist formation of disulfide bonds in reduced substrates under physiological conditions. ..
  31. Mikita T, Daniel C, Wu P, Schindler U. Mutational analysis of the STAT6 SH2 domain. J Biol Chem. 1998;273:17634-42 pubmed
    ..However, the two types of SH2 domains may differ at their C-terminal ends. ..
  32. Skelton N, Chen Y, Dubree N, Quan C, Jackson D, Cochran A, et al. Structure-function analysis of a phage display-derived peptide that binds to insulin-like growth factor binding protein 1. Biochemistry. 2001;40:8487-98 pubmed
    ..By comparison of alanine scanning data for IGF-I and the turn-helix peptide, we propose a model for common surface features of these molecules that recognize IGFBP-1. ..
  33. Ferrara N, Gerber H. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 2001;106:148-56 pubmed
    ..Substantial evidence also implicates VEGF in tumors and intraocular neovascular syndromes. Currently, several clinical trials are ongoing to test the hypothesis that inhibition of VEGF activity may be beneficial for these conditions. ..
  34. Leask A, Holmes A, Black C, Abraham D. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem. 2003;278:13008-15 pubmed
    ..Thus Smads, Ras/MEK/ERK, protein kinase C, and fibroblast-enriched factors that bind GAGGAATGG act together to drive the TGF-beta-mediated induction of CTGF in fibroblasts. ..
  35. LeCouter J, Lin R, Ferrara N. The role of EG-VEGF in the regulation of angiogenesis in endocrine glands. Cold Spring Harb Symp Quant Biol. 2002;67:217-21 pubmed
  36. Junutula J, De Mazière A, Peden A, Ervin K, Advani R, van Dijk S, et al. Rab14 is involved in membrane trafficking between the Golgi complex and endosomes. Mol Biol Cell. 2004;15:2218-29 pubmed
    ..Impairment of Rab14 function did not however affect transferrin uptake or recycling kinetics. Together, these findings suggest that Rab14 is involved in the biosynthetic/recycling pathway between the Golgi and endosomal compartments. ..
  37. Chu P, Wu J, Liao X, Pardo J, Zhao H, Li C, et al. A novel role for p21-activated protein kinase 2 in T cell activation. J Immunol. 2004;172:7324-34 pubmed
    ..Taken together, these results suggest a novel role for PAK2 as a positive regulator of T cell activation. ..
  38. Yang M, Zhong W, Srivastava N, Slavin A, Yang J, Hoey T, et al. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc Natl Acad Sci U S A. 2005;102:6027-32 pubmed
    ..Thus, LPA(2) and LPA(3) signal the proliferation of colon cancer cells through cPKC-mediated activation of the beta-catenin pathway. These results link LPA and its GPCRs to cancer through a major oncogenic signaling pathway. ..
  39. Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, et al. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol. 2009;18:11-21 pubmed publisher
    ..The continuous measure of HER2 protein levels over a broad dynamic range, and the novel HER2 homodimer measure, are presently being assessed as predictive markers for responses to targeted HER2 therapy. ..
  40. Demeule B, Shire S, Liu J. A therapeutic antibody and its antigen form different complexes in serum than in phosphate-buffered saline: a study by analytical ultracentrifugation. Anal Biochem. 2009;388:279-87 pubmed publisher
    ..In addition, omalizumab and IgE formed different complexes in serum than in phosphate-buffered saline in terms of both size and affinity. ..
  41. Basi G, Feinberg H, Oshidari F, Anderson J, Barbour R, Baker J, et al. Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J Biol Chem. 2010;285:3417-27 pubmed publisher
    ..These findings provide a structural basis for immunotherapeutic strategies targeting Abeta species postulated to underlie cognitive deficits in AD. ..
  42. Chen X, Nguyen M, Jacobson F, Ouyang J. Charge-based analysis of antibodies with engineered cysteines: from multiple peaks to a single main peak. MAbs. 2009;1:563-71 pubmed
  43. Hu Y, Ota N, Peng I, Refino C, Danilenko D, Caplazi P, et al. IL-17RC is required for IL-17A- and IL-17F-dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol. 2010;184:4307-16 pubmed publisher
    ..Finally, Il-17rc(-/-) mice develop much milder disease in an experimental autoimmune encephalomyelitis model, supporting an essential role for IL-17RC in mediating immune-mediated CNS inflammation. ..
  44. Cox J, Kljavin N, Ramamoorthi N, Diehl L, Batten M, Ghilardi N. IL-27 promotes T cell-dependent colitis through multiple mechanisms. J Exp Med. 2011;208:115-23 pubmed publisher
  45. Dueber E, Schoeffler A, Lingel A, Elliott J, Fedorova A, Giannetti A, et al. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science. 2011;334:376-80 pubmed publisher
    ..Antagonist binding induces conformational rearrangements that enable RING dimerization and formation of the active E3 ligase. ..
  46. Meng F, Evans J, Bhupathi D, Banica M, Lan L, Lorente G, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther. 2012;11:740-51 pubmed publisher
    ..Multicellular layers composed of mixtures of parental HCT116 cells and HCT116 cells engineered to express an oxygen-insensitive bacterial nitroreductase showed that TH-302 exhibits a significant bystander effect. ..
  47. Bressler N, Varma R, Doan Q, Gleeson M, Danese M, Bower J, et al. Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132:168-73 pubmed publisher
    ..Strategies to increase awareness are warranted, especially given the recent availability of improved therapies for DME. ..
  48. Hanan E, Baumgardner M, Bryan M, Chen Y, Eigenbrot C, Fan P, et al. 4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett. 2016;26:534-539 pubmed publisher
    ..Using an optimization strategy focused on structure-based design and improving PK properties through metabolite identification, we obtained advanced leads with high oral exposure. ..
  49. Vartanian S, Ma T, Lee J, Haverty P, Kirkpatrick D, Yu K, et al. Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis. Mol Cell Proteomics. 2016;15:1220-31 pubmed publisher
    ..In conclusion, our data show that the activity of brusatol is not restricted to Nrf2 but, rather, functions as a global protein synthesis inhibitor. ..
  50. D Souza W, Douangpanya J, Mu S, Jaeckel P, Zhang M, Maxwell J, et al. Differing roles for short chain fatty acids and GPR43 agonism in the regulation of intestinal barrier function and immune responses. PLoS ONE. 2017;12:e0180190 pubmed publisher
    ..These findings demonstrate that SCFA possess broad protective functions in IBD and agonizing GPR43 alone is unlikely to be beneficial in patients. ..
  51. Yang Y, Fu A, Wu X, Reagan J. GPR35 is a target of the loop diuretic drugs bumetanide and furosemide. Pharmacology. 2012;89:13-7 pubmed publisher
    ..These findings suggest that GPR35 may play an important role in skin cell biology and be a potential target for the treatment of a variety of immune disorders. ..
  52. Gorman C, Gies D, McCray G, Huang M. The human cytomegalovirus major immediate early promoter can be trans-activated by adenovirus early proteins. Virology. 1989;171:377-85 pubmed
    ..Increases in expression due to E1a and E1b proteins were additive. These results suggest that adenovirus early expression can activate quiescent HCMV sequences. ..
  53. Zhang D, Sliwkowski M, Mark M, Frantz G, Akita R, Sun Y, et al. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci U S A. 1997;94:9562-7 pubmed
    ..The expression of NRG3 is highly restricted to the developing and adult nervous system. These data suggest that NRG3 is a novel, neural-enriched ligand for ErbB4. ..
  54. Wesche H, Gao X, Li X, Kirschning C, Stark G, Cao Z. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem. 1999;274:19403-10 pubmed
    ..The discovery of IRAK-M adds another level of complexity to our understanding of signaling by members of the Toll/IL-1 receptor family. ..
  55. Navas T, Baldwin D, Stewart T. RIP2 is a Raf1-activated mitogen-activated protein kinase kinase. J Biol Chem. 1999;274:33684-90 pubmed
    ..These results describe a novel pathway of ERK activation and the first catalytic function ascribed to any of the RIP-like kinases associated with the TNF receptor superfamily. ..
  56. Ernst J, Li H, Kim H, Nakamura G, Yansura D, Vandlen R. Isolation and characterization of the B-cell marker CD20. Biochemistry. 2005;44:15150-8 pubmed
    ..Such cross-linking may play a role in partitioning CD20 into lipid rafts and in enhancing antibody-dependent B-cell depletion activities of rituximab and other therapeutic anti-CD20 antibodies. ..
  57. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell. 2005;123:931-44 pubmed
    ..Thus, TWEAK suppresses production of IFN-gamma and IL-12, curtailing the innate response and its transition to adaptive TH1 immunity. ..
  58. Wood K, Lad L, Luo L, Qian X, Knight S, Nevins N, et al. Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci U S A. 2010;107:5839-44 pubmed publisher
    ..Consistent with genetic studies in mice suggesting that decreased CENP-E function can have a tumor-suppressive effect, inhibition of CENP-E induced tumor cell apoptosis and tumor regression. ..
  59. Young J, Yu X, Wolslegel K, Nguyen A, Kung C, Chiang E, et al. Lymphotoxin-alphabeta heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis. Cytokine. 2010;51:78-86 pubmed publisher
    ..Therefore, soluble LTalphabeta in synovial fluid is associated with a proinflammatory cytokine milieu that contributes to synovitis in RA. ..
  60. Singh M, Lima A, Molina R, Hamilton P, Clermont A, Devasthali V, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol. 2010;28:585-93 pubmed publisher
  61. Rosen D, Minden M, Kornblau S, Cohen A, Gayko U, Putta S, et al. Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). PLoS ONE. 2010;5:e13543 pubmed publisher
    ..These studies show the feasibility of SCNP to assess modulated intracellular signaling pathways and characterize the biology of individual AML samples in the context of genetic alterations. ..
  62. Scheerens H, Su Z, Irving B, Townsend M, Zheng Y, Stefanich E, et al. MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments. Arthritis Res Ther. 2011;13:R177 pubmed publisher
    ..The maximum tolerated dose of MTRX1011A was 1.5 mg/kg SC administered weekly. At this dose MTRX1011A did not achieve maximum PD activity expected to be required for reduction in disease activity. ..
  63. Chou M, Austin C, Kim J. Collective action of hematopoietic cell subsets mediates anti-IL10R1 and CpG tumor immunity. Cancer Immunol Immunother. 2012;61:1055-64 pubmed publisher
  64. Mathias S, Crosby R, Zazzali J, Maurer M, Saini S. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012;108:20-24 pubmed publisher
    ..80. Known-groups validity was supported for most UAS scores; and construct validity was demonstrated by relationships with collateral measures. The enhanced UAS has adequate measurement properties to support its use in clinical research. ..
  65. Pastuskovas C, Mundo E, Williams S, Nayak T, Ho J, Ulufatu S, et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther. 2012;11:752-62 pubmed publisher
    ..These findings may ultimately help inform dosing strategies to achieve improved clinical outcomes. ..
  66. Safina B, Baker S, Baumgardner M, Blaney P, Chan B, Chen Y, et al. Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition. J Med Chem. 2012;55:5887-900 pubmed publisher
    ..We describe a variety of strategies and methods for monitoring and attenuating TDI. Ultimately, a structure-based design approach was employed to identify a suitable structural replacement for further optimization. ..
  67. Kozak K, Wang J, Lye M, Chuh J, Takkar R, Kim N, et al. Micro-volume wall-less immunoassays using patterned planar plates. Lab Chip. 2013;13:1342-50 pubmed publisher
    ..PPPs therefore represent an attractive and broadly applicable approach to flexible miniaturization of plate-based immunochemical assays. ..
  68. Xiao Y, Ramiscal J, Kowanetz K, Del Nagro C, Malek S, Evangelista M, et al. Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor. Mol Cancer Ther. 2013;12:2285-95 pubmed publisher
    ..In conclusion, our results show that selection of an appropriate agent to combine with a CHK1 inhibitor needs to be carefully evaluated in the context of the genetic background and tumor type in which it will be used. ..
  69. Gonzalez A, Li Z, Beck H, Canon J, Chen A, Chow D, et al. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres. J Med Chem. 2014;57:2963-88 pubmed publisher
    ..Optimization efforts toward the discovery of these inhibitors as well as the new interactions observed with the MDM2 protein are described herein. ..
  70. Zhou M, Wang X, Phung V, Lindhout D, Mondal K, Hsu J, et al. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19. Cancer Res. 2014;74:3306-16 pubmed publisher
    ..Our results suggest that selectively targeting the FGF19-FGFR4 pathway may offer a tractable approach to improve the treatment of chronic liver disease and cancer. ..
  71. Young W, Barbosa J, Blomgren P, Bremer M, Crawford J, Dambach D, et al. Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability. Bioorg Med Chem Lett. 2016;26:575-579 pubmed publisher
    ..The most promising substituted aryl linkers were then incorporated into an optimized pyridazinone scaffold, resulting in the identification of lead analog 23, possessing improved potency, metabolic stability and preclinical properties. ..
  72. Holt A, Wootton S, Mulero J, Brzoska P, Langit E, Green R. Developmental validation of the Quantifiler(®) HP and Trio Kits for human DNA quantification in forensic samples. Forensic Sci Int Genet. 2016;21:145-57 pubmed publisher
  73. Lewis M, Tartaglia L, Lee A, Bennett G, Rice G, Wong G, et al. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci U S A. 1991;88:2830-4 pubmed
    ..This result suggests that the various activities of human tumor necrosis factor alpha reported in mice or in murine cell lines are probably mediated by mTNF-R1. ..
  74. Oltersdorf T, Fritz L, Schenk D, Lieberburg I, Johnson Wood K, Beattie E, et al. The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II. Nature. 1989;341:144-7 pubmed
    ..Secreted APP695 did not form complexes with trypsin. We conclude that the secreted form of APP with the Kunitz protease inhibitor domain is PN-II. ..
  75. Park J, Keller G, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993;4:1317-26 pubmed
    ..ECM-bound VEGF189 and VEGF206 have molecular masses consistent with the intact polypeptides. The ECM may represent an important source of VEGF and angiogenic potential. ..
  76. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel D. TRAF6 is a signal transducer for interleukin-1. Nature. 1996;383:443-6 pubmed
    ..These findings indicate that TRAF proteins may function as signal transducers for distinct receptor families and that TRAF6 participates in IL-1 signalling. ..
  77. Pitti R, Marsters S, Lawrence D, Roy M, Kischkel F, Dowd P, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699-703 pubmed
    ..Thus, certain tumours may escape FasL-dependent immune-cytotoxic attack by expressing a decoy receptor that blocks FasL. ..
  78. Nitta M, Ku S, Brown C, Okamoto A, Shan B. CPF: an orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7alpha-hydroxylase gene. Proc Natl Acad Sci U S A. 1999;96:6660-5 pubmed
    ..Cotransfection of a CPF expression plasmid and a CYP7A reporter gene resulted in specific induction of CYP7A-directed transcription. These observations suggest that CPF is a key regulator of human CYP7A gene expression in the liver. ..
  79. Li Y, Pursell Z, Linn S. Identification and cloning of two histone fold motif-containing subunits of HeLa DNA polymerase epsilon. J Biol Chem. 2000;275:23247-52 pubmed
    ..p17 together with p12, but not p17 or p12 alone, interact with both p261 and p59 subunits of HeLa pol epsilon. The genes for p17 and p12 can be assigned to chromosome locations 9q33 and 2p12, respectively. ..
  80. Seshasayee D, Valdez P, Yan M, Dixit V, Tumas D, Grewal I. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity. 2003;18:279-88 pubmed
    ..These results demonstrate the critical requirement for TACI in regulating B cell homeostasis. ..
  81. Strelow A, Kollewe C, Wesche H. Characterization of Pellino2, a substrate of IRAK1 and IRAK4. FEBS Lett. 2003;547:157-61 pubmed
    ..However, unlike Pellino1, Pellino2 does not seem to activate a specific transcription factor, but links TIR signaling to basic cellular processes. ..
  82. Wallweber H, Compaan D, Starovasnik M, Hymowitz S. The crystal structure of a proliferation-inducing ligand, APRIL. J Mol Biol. 2004;343:283-90 pubmed
    ..0 and 8.5. Modeling of the APRIL-BCMA complex shows the resulting interface is in agreement with mutagenesis data. ..
  83. Wesche H, Xiao S, Young S. High throughput screening for protein kinase inhibitors. Comb Chem High Throughput Screen. 2005;8:181-95 pubmed
    ..The majority of this review is dedicated to a detailed description and discussion of the various assay formats currently being employed for high throughput screening. ..
  84. Wu X, Ge H, Lemon B, Vonderfecht S, Weiszmann J, Hecht R, et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem. 2010;285:5165-70 pubmed publisher
    ..These data suggest that activation of FGFR4 is the mechanism whereby FGF19 can increase hepatocyte proliferation and induce hepatocellular carcinoma formation. ..
  85. Ong C, Jubb A, Zhou W, Haverty P, Harris A, Belvin M, et al. p21-activated kinase 1: PAK'ed with potential. Oncotarget. 2011;2:491-6 pubmed
    ..We further discuss mechanisms by which inhibition of PAK1 can arrest tumor growth and promote cell apoptosis, and the types of cancers in which PAK1 inhibition may hold promise. ..
  86. La Porte S, Bollini S, Lanz T, Abdiche Y, Rusnak A, Ho W, et al. Structural basis of C-terminal ?-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol. 2012;421:525-36 pubmed publisher
    ..These findings provide novel structural insights into the in vivo conformation of the C-terminus of A?40 and the brain A?-lowering efficacy that we observed following administration of ponezumab in transgenic mouse models. ..
  87. Adler A, McCleland M, Truong T, Lau S, Modrusan Z, Soukup T, et al. CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. Cancer Res. 2012;72:2129-39 pubmed publisher
    ..This raises the intriguing possibility that targeting CDK8 therapeutically may specifically inhibit the stem-like properties of cancer cells. ..
  88. Loyet K, DeForge L, Katschke K, Diehl L, Graham R, Pao L, et al. Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53:6628-37 pubmed
    ..Increased activation of the alternative complement pathway in vitreous was controlled by disease stage and genetic variation in the complement pathway, supporting a role for complement activation in AMD disease pathogenesis. ..
  89. Munugalavadla V, Mariathasan S, Slaga D, Du C, Berry L, Del Rosario G, et al. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. Oncogene. 2014;33:316-25 pubmed publisher
    ..These data provide a clear therapeutic hypothesis for the inhibition of PI3K and provide a rationale for clinical development of GDC-0941 in myeloma. ..
  90. Jaiswal B, Kljavin N, Stawiski E, Chan E, Parikh C, Durinck S, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013;23:603-17 pubmed publisher
    ..Furthermore, we found that anti-ERBB antibodies and small molecule inhibitors effectively blocked mutant ERBB3-mediated oncogenic signaling and disease progression in vivo. ..
  91. Wu L, Zepp J, Qian W, Martin B, Ouyang W, Yin W, et al. A novel IL-25 signaling pathway through STAT5. J Immunol. 2015;194:4528-34 pubmed publisher
    ..Together, these findings reveal a novel Act1-independent IL-25 signaling pathway through STAT5 activation. ..
  92. Zheng C, Zheng L, Yoo J, Guo H, Zhang Y, Guo X, et al. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell. 2017;169:1342-1356.e16 pubmed publisher
    ..This compendium of transcriptome data provides valuable insights and a rich resource for understanding the immune landscape in cancers. ..